These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22162109)

  • 21. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
    Maignan S; Guilloteau JP; Choi-Sledeski YM; Becker MR; Ewing WR; Pauls HW; Spada AP; Mikol V
    J Med Chem; 2003 Feb; 46(5):685-90. PubMed ID: 12593649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
    Steuber H; Heine A; Klebe G
    J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.
    Rezaie AR
    Biochemistry; 2004 Mar; 43(12):3368-75. PubMed ID: 15035608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
    Wan ZK; Lee J; Xu W; Erbe DV; Joseph-McCarthy D; Follows BC; Zhang YL
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4941-5. PubMed ID: 16806920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites.
    Zürcher M; Diederich F
    J Org Chem; 2008 Jun; 73(12):4345-61. PubMed ID: 18510366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The extended interactions and Gla domain of blood coagulation factor Xa.
    Wang SX; Hur E; Sousa CA; Brinen L; Slivka EJ; Fletterick RJ
    Biochemistry; 2003 Jul; 42(26):7959-66. PubMed ID: 12834348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets.
    Murcia M; Morreale A; Ortiz AR
    J Med Chem; 2006 Oct; 49(21):6241-53. PubMed ID: 17034130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition.
    Lin Z; Johnson ME
    FEBS Lett; 1995 Aug; 370(1-2):1-5. PubMed ID: 7649284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.
    Moretto AF; Kirincich SJ; Xu WX; Smith MJ; Wan ZK; Wilson DP; Follows BC; Binnun E; Joseph-McCarthy D; Foreman K; Erbe DV; Zhang YL; Tam SK; Tam SY; Lee J
    Bioorg Med Chem; 2006 Apr; 14(7):2162-77. PubMed ID: 16303309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
    Katakura S; Nagahara T; Hara T; Iwamoto M
    Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Na+ binding channel of human coagulation proteases: novel insights on the structure and allosteric modulation revealed by molecular surface analysis.
    Silva FP; Antunes OA; de Alencastro RB; De Simone SG
    Biophys Chem; 2006 Feb; 119(3):282-94. PubMed ID: 16288954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
    J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-phenylglycinol-derived non-covalent factor Xa inhibitors: effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity.
    Klimkowski VJ; Watson BM; Wiley MR; Liebeschuetz J; Franciskovich JB; Marimuthu J; Bastian JA; Sall DJ; Smallwood JK; Chirgadze NY; Smith GF; Foster RS; Craft T; Sipes P; Chastain M; Sheehan SM
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5801-5. PubMed ID: 17881231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents.
    Prasad V; Birzin ET; McVaugh CT; Van Rijn RD; Rohrer SP; Chicchi G; Underwood DJ; Thornton ER; Smith AB; Hirschmann R
    J Med Chem; 2003 May; 46(10):1858-69. PubMed ID: 12723949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
    Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.
    Kohrt JT; Filipski KJ; Cody WL; Cai C; Dudley DA; Van Huis CA; Willardsen JA; Rapundalo ST; Saiya-Cork K; Leadley RJ; Narasimhan L; Zhang E; Whitlow M; Adler M; McLean K; Chou YL; McKnight C; Arnaiz DO; Shaw KJ; Light DR; Edmunds JJ
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4752-6. PubMed ID: 16125385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.